Figure 5.

Bioavailability of DMF and MMF and in vivo activation of ARE-containing genes by DMF. A, Levels of MMF in the brain, liver, and blood of C57BL/6 mice after two doses of 50 mg/kg (or 100 mg · kg⁻¹ · d⁻¹) DMF or MMF administered 12 h apart by oral gavage and measured at 6 h after the last dose. Bars represent mean ± SEM (n = 5 mice per group). *p < 0.05 compared with respective vehicle controls. B, Quantitative RT-PCR showing relative mRNA levels of ARE-containing genes in the ventral midbrain and liver after two doses of 50 mg/kg DMF administered 12 h apart by oral gavage and measured at 6 h after the last dose. Bars represent mean ± SEM (n = 5 mice per group). *p < 0.05 compared with vehicle controls.